"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A study to find a new way to diagnose cancer of the ovaries and womb (CTCR OV05)
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This study is looking at finding a new way to diagnose cancer of the ovaries and lining of the womb (endometrial cancer).
This study is open to women have been referred to Addenbrooke’s Hospital because they may have ovarian cancer. And for women who are having surgery at Addenbrooke’s Hospital to remove ovarian cancer or endometrial cancer.
More about this trial
Doctors use a blood test called CA125 followed by a transvaginal ultrasound scan to diagnose ovarian cancer. They also use a transvaginal ultrasound to diagnose endometrial cancer and they may take a small piece of tissue (
We know from research that small pieces of
In this study the researchers want to find out if doctors can use these samples to better diagnose and treat these cancers.
To do this they first need to know if it is possible to find these changes in the blood and the mucus of the cervix of women when they are diagnosed with these cancers.
Who can enter
You may be able to join this study if you are woman who is at least 18 years old and one of the following apply
This is a feasibility study. The researchers need 230 women to join.
The study team will ask for some blood samples, a
For women who are having surgery to remove their cancer, your surgeon will take the cervical smear and mucus samples during the operation. The researchers will take a blood sample before your operation and then every day you are in hospital after your operation.
There are no extra hospital visits if you take part in the study.
You may feel some discomfort and have a slight bruising where the blood samples were taken.
Taking the mucus samples is the same as having a cervical smear test.
How to join a clinical trial
Cambridge University Hospitals NHS Foundation Trust
Medical Research Council (MRC)
Target Ovarian Cancer
University of Cambridge